Dr Jim Faulkner joins Vitarka’s Board as Non-executive Director

Vitarka Therapeutics Ltd, a preclinical stage Biotech company developing targeted non-viral delivery technology has appointed Jim Faulkner as a new Non-Executive Director to its Board of Directors.

Dr Faulkner has previously held positions at Apple Tree Partners, Ascidian Therapeutics, Autolus Ltd, and GSK, where he was involved in the development of over 25 therapeutics including gene therapy and CAR-T assets that successfully reached the clinic. Jim’s skills in leading advanced therapy and biopharmaceutical development together with his experience in growing biotech companies will further strengthen the existing skills and expertise of the Vitarka Therapeutics team.

Vineeta Tripathi, CEO of Vitarka Therapeutics:
“I welcome Jim to our Board of Directors. His deep domain expertise and knowledge is a great value-add to Vitarka’s leadership team. Jim brings a wealth of experience in steering our pipeline and accelerating product development. He has joined us at a crucial time as Vitarka is set to nominate a lead asset for IND-enabling studies. I am grateful for Jim’s contribution on the Board as well as going above and beyond by contributing to our ongoing scientific and manufacturing activities.”

Jim Faulkner, NED of Vitarka Therapeutics:
I am delighted to be joining the Vitarka Board of Directors. Efficient intracellular delivery of large macromolecules has been a challenge that has held back the field in achieving its full potential. Vitarka’s EndoPore technology could be a significant breakthrough that could enable innovative products capable of transforming patient outcomes. Vineeta and team have made a great start and I look forward to being part of the future growth of Vitarka Therapeutics.